Table 2.
Outcome of anti-PD1 antibody treatment (n = 70).
| Variable | N (%) |
|---|---|
| Treatment duration (months) | |
| Median | 11.8 |
| Range | 3–33 |
| Response at cessation | |
| Complete Response | 61 (87) |
| Partial Response | 6 (8.6) |
| Stable Disease | 3 (4.3) |
| Time to BOR (months) | |
| Median | 5 |
| Range | 1–29 |
| Time to CR (n= 61) (months) | |
| Median | 5 |
| Range | 1–29 |
| PD post cessation | |
| No | 57 (81) |
| Yes | 13 (19) |
| Follow up post cessation (months) | |
| Median | 34.2 |
| Range | 2–70.8 |
| Treatment free survival (months) | |
| Median | Not reached |
| Range | 2–70.2 |
| Time to PD after cessation (n=13) (months) | |
| Median | 11.1 |
| Range | 2.2–27.8 |
| PFS (months) | |
| Median | Not reached |
| Range | 6–81.8 |
| OS (months) | |
| Median | Not reached |
| Range | 6.3–81.8 |